Top Markets
Coin of the day
NightHawk Biosciences, Inc. NightHawk Biosciences, Inc.

NightHawk Biosciences, Inc.

NHWK
Kedudukan dalam Saham #33280
NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm,... NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm, dedicated to advancing immune therapies and vaccines. Their core mission involves leveraging and modifying the body's immune system to combat a range of illnesses, particularly various cancers and infectious diseases. Central to their strategy is the proprietary gp96 platform. This platform encompasses two key technologies: ImPACT, an allogeneic (off-the-shelf) cell-based system designed to activate and expand T-cells, acting as a broad immune stimulant; and ComPACT, which combines antigen-specific T-cell activation with targeted co-stimulation in a single product. NightHawk's clinical pipeline features several promising candidates: HS-110, which has completed enrollment for its Phase II clinical trial, targeting advanced non-small cell lung cancer; and HS-130, currently undergoing a Phase I clinical trial for advanced solid tumors. Additionally, PTX-35, a novel T-cell co-stimulator agonist antibody that specifically targets DR3/TNFRSF25, is also in Phase I development. The company is also exploring DR3/TNFRSF25 as a general target for various immunotherapy applications. Beyond these, a COVID-19 vaccine is currently in preclinical stages. A notable collaboration involves Dr. James Shapiro at the University of Alberta, focusing on the manufacturing of a surrogate mouse version of PTX-35. Originally established as Heat Biologics, Inc. in 2008, the company rebranded to NightHawk Biosciences, Inc. in May 2022. Its headquarters are located in Morrisville, North Carolina.
Harga Saham
$0.3136
Disegerakkan terakhir: 2024-03-04
Modal Pasaran
$7.97M
Perubahan (1 hari)
-3.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan NightHawk Biosciences, Inc. (NHWK)

Kategori

Pendapatan untuk NightHawk Biosciences, Inc. (NHWK)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini NightHawk Biosciences, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi NightHawk Biosciences, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE